A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies

Clin Cancer Res. 2020 Feb 15;26(4):761-763. doi: 10.1158/1078-0432.CCR-19-3670. Epub 2019 Dec 16.

Abstract

CDK9-specific inhibition with AZD4573 impairs cancer-promoting gene expression such as MCL-1 and has been proven effective in hematologic malignancies preclinical models. This new clinical candidate should be further explored in the clinic not only as a monotherapy but also in combination with BH3 mimetics to prevent treatment resistance.See related article by Cidado et al., p. 922.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antineoplastic Agents*
  • Apoptosis / drug effects
  • Cyclin-Dependent Kinase 9
  • Hematologic Neoplasms*
  • Humans
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Protein Kinase Inhibitors

Substances

  • Antineoplastic Agents
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Protein Kinase Inhibitors
  • CDK9 protein, human
  • Cyclin-Dependent Kinase 9